CM – Sarepta increases sales forecast for 2021 by $ 40 million due to strong sales of muscular dystrophy drugs

0

Similar title :
Sarepta Increases Sales in 2021 Forecast of $ 40 Million of Strong Muscular Dystrophy Drugs Sales
Sarepta Therapeutics Announces Third Quarter 2021 Financial Results and Latest Company Developments
Sarepta Therapeutics Reports Q3 Net Product Sales of 166.9 million USD

Keywords:

Sarepta Therapeutics Inc,NASDAQ:SRPT,Revenue,2021,Sarepta Therapeutics Inc, NASDAQ:SRPT, Revenue, 2021,,

Donnez votre avis et abonnez-vous pour plus d’infos

Vidéo du jour: